AstraZeneca

News

Blow for AstraZeneca as cancer combination fails

After several years of growing expectation, AstraZeneca’s long-awaited MYSTIC immune-oncology trial has failed to show benefit over standard lung cancer therapy.

News

AstraZeneca CEO Soriot may stay after all

Soriot to host results announcement as usual

News

AZ CEO set to take charge at Teva - report

Report raises concerns about outcome of MYSTIC trial.

News

Piece in form of UK borders torn out from the flag of the European Union. United Kingdom withdrawal from the European Union. Brexit concept

UK ministers seek a soft Brexit for pharma

Health and business secretaries commit to close working with EMA

News

Clovis looks for new drugs after Rubraca success

US biotech looks to bolster pipeline.

News

AstraZeneca Amenities Building - Mississauga - Sept 2005
Non exclusive, unlimited time license for print & web to WZMH Architects

AZ sells migraine drug rights to Grunenthal for $300m

AZ says migraine outside its strategic focus.

Blow for AstraZeneca as cancer combination fails

AstraZeneca CEO Soriot may stay after all

AZ CEO set to take charge at Teva - report

UK ministers seek a soft Brexit for pharma

Clovis looks for new drugs after Rubraca success

AZ sells migraine drug rights to Grunenthal for $300m

Test could end uncertainty in inherited muscle diseases

Discover a new era of healthcare panel engagement: Grounded ...

AstraZeneca

Editor's Picks